"Specializing in Diabetes and Endocrine Disorders"

During the past decade, Capital Diabetes and Endocrine Associates conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Capital Diabetes and Endocrine Associates" are "Diabetes Mellitus" (1 trials), "Diabetes Mellitus, Type 2" (1 trials), "Gastroparesis" (1 trials) and "Type 2 Diabetes" (1 trials). Many other conditions were trialed in "Capital Diabetes and Endocrine Associates" in a lesser frequency.

Most popular intervention types in "Capital Diabetes and Endocrine Associates" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Canagliflozin 100 mg" (1 trials), "Canagliflozin 300 mg" (1 trials), "Insulin Glargine (U100)" (1 trials) and "Insulin Lispro (U100)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Capital Diabetes and Endocrine Associates" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Capital Diabetes and Endocrine Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Capital Diabetes and Endocrine Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Capital Diabetes and Endocrine Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".